Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Comprehensive Review On Cyclodextrin-Based Carriers For Delivery Of Chemotherapeutic Cytotoxic Anticancer Drugs

B. Gidwani, Amber Vyas
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Most of the cytotoxic chemotherapeutic agents have poor aqueous solubility. These molecules are associated with poor physicochemical and biopharmaceutical properties, which makes the formulation difficult. An important approach in this regard is the use of combination of cyclodextrin and nanotechnology in delivery system. This paper provides an overview of limitations associated with anticancer drugs, their complexation with cyclodextrins, loading/encapsulating the complexed drugs into carriers, and various approaches used for the delivery. The present review article aims to assess the utility of cyclodextrin-based carriers like liposomes, niosomes, nanoparticles, micelles, millirods, and siRNA for delivery of antineoplastic agents. These systems based on cyclodextrin complexation and nanotechnology will camouflage the undesirable properties of drug and lead to synergistic or additive effect. Cyclodextrin-based nanotechnology seems to provide better therapeutic effect and sustain long life of healthy and recovered cells. Still, considerable study on delivery system and administration routes of cyclodextrin-based carriers is necessary with respect to their pharmacokinetics and toxicology to substantiate their safety and efficiency. In future, it would be possible to resolve the conventional and current issues associated with the development and commercialization of antineoplastic agents.
This paper references
10.1016/j.ejpb.2009.11.011
Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide.
N. Elgindy (2010)
10.1016/S0022-2860(02)00236-3
Rigidity versus flexibility. A review of experimental and theoretical studies pertaining to the cyclodextrin nonrigidity
H. Dodziuk (2002)
Expression of the c-erbB-3 protein in normal human adult and fetal tissues.
S. A. Prigent (1992)
10.1111/J.2042-7158.1997.TB00499.X
Physicochemical and Biological Studies of Inclusion Complex of Methotrexate with β‐Cyclodextrin
U. V. Singh (1997)
10.1016/j.ejpb.2009.11.003
Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity.
S. Swaminathan (2010)
10.1586/14737159.8.4.387
Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis
O. K. Okamoto (2008)
10.1053/CTRV.1998.0107
Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
J. M. Terwogt (1999)
10.1271/bbb.69.246
Interaction of Modified Cyclodextrins with Cytochrome P-450
M. Ishikawa (2005)
Synthesis and Characterization studies of Cisplatin/HydroxypropylβCyclodextrin Complex
A. Balaji (2009)
10.1016/j.biomaterials.2008.09.035
The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs.
F. Quaglia (2009)
10.1023/A:1012788432106
The Chlorhexidine: beta;-Cyclodextrin Inclusion Compound: Preparation, Characterization and Microbiological Evaluation
M. Cortés (2001)
10.1073/pnas.2036503100
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
T. Johns (2003)
10.1208/pt060243
Cyclodextrins in drug delivery: An updated review
R. Challa (2008)
10.1007/s11095-010-0233-4
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
C. Oerlemans (2010)
Nanoparticles: Colloidal Drug Delivery
J. Kreuter (1994)
10.1016/J.JPBA.2005.01.030
Improving the solubility of ampelopsin by solid dispersions and inclusion complexes.
Li-ping Ruan (2005)
10.1016/j.bbamem.2009.08.015
Enhancement of transdermal drug delivery via synergistic action of chemicals.
P. Karande (2009)
Cyclodextrinbased polymers for therapeutic delivery
A.Glucksmann (2012)
ulating β - lapachone release from polymer millirods through cyclodextrin complexation
F. Wang (2006)
10.1182/BLOOD-2004-07-2784
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
R. Walter (2005)
Cyclodextrins: application in different routes of drug administration.
S. Shimpi (2005)
10.1023/B:PHAM.0000016235.32639.23
Solubilizing Excipients in Oral and Injectable Formulations
R. Strickley (2004)
Cyclodextrinbased siRNA delivery nanocarriers: a state-of-the-art review
K. Chaturvedi (2011)
10.1016/S0032-9592(03)00258-9
Cyclodextrins and their uses: a review
E. D. Valle (2004)
10.1200/JCO.2008.17.7436
Cancer stem cells: a step toward the cure.
B. Boman (2008)
10.1016/J.CARBPOL.2010.10.033
Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin
E. E. M. Eid (2011)
10.1517/17425247.2011.610790
Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review
K. Chaturvedi (2011)
10.1111/j.1365-2710.2009.01095.x
Solubilization of vorinostat by cyclodextrins
Y. Cai (2010)
Targeting cancer stem cells with monoclonal antibodies: a newperspective in cancer therapy and diagnosis
O. K. Okamoto (2008)
10.1124/JPET.104.071845
Effects of γ- and Hydroxypropyl-γ-cyclodextrins on the Transport of Doxorubicin across an in Vitro Model of Blood-Brain Barrier
V. Monnaert (2004)
10.1007/BF00660751
Cyclodextrin polymers in the pharmaceutical industry
É. Fenyvesi (1988)
10.1016/J.IJPHARM.2005.01.009
Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-beta-cyclodextrin.
J. Manosroi (2005)
10.1080/10611860600711136
Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes
Hidetoshi Arima (2006)
10.1208/ps060107
β-cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies
M. Reddy (2008)
Antibodies, " in Chemotherapy and Biotherapy: Principles and Practice
D A Scheinberg (2011)
10.1016/j.nano.2011.07.011
Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma.
S. Dhule (2012)
Niosome entrapped ß-cyclodextrin methotrexate complex as a drug delivery system
Oommen Elsie (1999)
Comparison of the complexation of cosmetic and pharmaceutical compounds with -cyclodextrin, 2-hydroxypropyl--cyclodextrin and water-soluble--cyclodextrin-coepichlorohydrin polymers
A M Layre (2002)
10.1021/JS990128I
Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
F. Hirayama (1999)
10.1021/CR970022C
Introduction and General Overview of Cyclodextrin Chemistry.
J. Szejtli (1998)
10.1021/JS9704341
Spontaneous opalescence of aqueous gamma-cyclodextrin solutions: complex formation or self-aggregation?
L. Szente (1998)
10.1248/BPB.24.395
A moderate interaction of maltosyl-alpha-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin.
N. Ono (2001)
Biopharmaceutical Classification System : An Account
Mohd Yasir (2003)
10.1016/j.ejps.2009.09.010
Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel.
M. Agüeros (2009)
10.1158/0008-5472.SABCS-3136
A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer.
I. Krop (2009)
10.1016/S0378-5173(99)00255-0
New injectable melphalan formulations utilizing (SBE)7m-β-CD or HP-β-CD
David Q. Ma (1999)
10.1111/J.1470-9465.2004.00838.X
Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity.
J. Donnelly (2004)
10.1016/j.ejpb.2012.06.001
Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.
D. Paolino (2012)
10.1016/j.actbio.2010.08.029
A hydrotropic β-cyclodextrin grafted hyperbranched polyglycerol co-polymer for hydrophobic drug delivery.
X. Zhang (2011)
A phase I study of trastuzumab-DM1, a first-in-class HER2 antibodydrug conjugate (ADC), given every 3 weeks to patients with HER2+ metastatic breast cancer
M Beeram (2008)
10.1111/j.1365-2710.2008.00970.x
Inhaled corticosteroids for asthma: are they all the same?
A. Baptist (2009)
10.1016/J.EJPS.2006.10.008
Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities.
S. Béni (2007)
10.1038/nbt1204-1597
Antibodies
IgM μ-Chain (2004)
10.1007/S10847-006-9259-Y
Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer
E. Bilensoy (2007)
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
M. Press (1990)
BioMed Research International
New injectable melphalan formulations utilizing (SBE) 7í µí±š -í µí»½-CD or HP-í µí»½-CD
D Q Ma (1999)
10.1016/S0939-6411(02)00061-9
Melt extrusion: from process to drug delivery technology.
J. Breitenbach (2002)
10.1615/CRITREVTHERDRUGCARRIERSYST.V20.I5.20
Polymeric micelles for delivery of poorly water-soluble compounds.
G. Kwon (2003)
10.1016/S0304-4165(96)00096-7
Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-beta-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery.
B. McCormack (1996)
10.1051/PARASITE/200108S2188
Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes.
J. A. García-Rodriguez (2001)
Design of Nanoparticles as Drug Carriers for Cancer Therapy.
J. Zhang (2006)
10.1039/C2NJ40851A
Fully supramolecular vesicles as anticancer drug delivery systems
A. Pourjavadi (2013)
10.1016/S1773-2247(10)50046-7
Cyclodextrins in drug delivery systems
F. Otero-Espinar (2010)
Cyclodextrinbased supramolecular polymers,”Chemical
A. Harada (2009)
10.1002/BDD.1803
Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus
P. Langguth (2012)
10.1016/S0168-3659(99)00248-5
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
Cyclodextrins and their inclusion complexes
J. Szejtli (1982)
10.1038/ASIAMAT.2010.84
Self-assembled supramolecular hydrogels based on polymer-cyclodextrin inclusion complexes for drug delivery
J. Li (2010)
10.1021/JS960075U
Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery.
R. Rajewski (1996)
10.1016/j.carbpol.2013.02.046
β-Cyclodextrin conjugated magnetic, fluorescent silica core-shell nanoparticles for biomedical applications.
A. Z. M. Badruddoza (2013)
10.1016/S0939-6411(00)00076-X
Improving drug solubility for oral delivery using solid dispersions.
C. Leuner (2000)
10.1016/j.colsurfb.2013.09.035
Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer.
B. Gidwani (2014)
10.1002/CJOC.201090223
Photostability Study of Doxorubicin Aqueous Solution Enhanced by Inclusion Interaction between Doxorubicin and Hydroxypropyl‐β‐cyclodextrin
Mingli Peng (2010)
10.1517/14712598.8.8.1151
Approved monoclonal antibodies for cancer therapy
M. Boyiadzis (2008)
10.1016/S0960-894X(99)00150-X
Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line.
A. al-Omar (1999)
10.1007/s10847-011-0101-9
In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation
B. Mognetti (2012)
Comparison of the complexation of cosmetic and pharmaceutical compounds with β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and water-soluble-β-cyclodextrin-coepichlorohydrin polymers
A. M. Layre (2002)
Hollow nanospheres fabricated from í µí»½-cyclodextrin-grafted í µí»¼, í µí»½-poly (aspartic acid) as the carrier of camptothecin
J Zeng (2013)
Nanoparticles: Colloidal Drug Delivery Systems
J Kreuter (1994)
Recent Trends in Niosome as Vesicular Drug Delivery System
Anchal Sankhyan (2012)
Cyclodextrinbased supramolecular polymers
A Harada (2009)
10.1016/j.ijpharm.2011.05.056
Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.
Y. Jiang (2011)
Pharmacokinetics of Injectable Beta - Cyclodextrin - Oridonin Inclusion Complex, A Novel Formulation of Oridonin in Wistar Rats
Bqoqu Li (2012)
10.1038/sj.bjc.6604483
Tumour-targeted nanomedicines: principles and practice
T. Lammers (2008)
10.1016/j.ijpharm.2010.07.046
Alternative oral exemestane formulation: improved dissolution and permeation.
B. Yavuz (2010)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1016/J.JCONREL.2007.01.019
A mechanistic model of controlled drug release from polymer millirods: effects of excipients and complex binding.
Fangjing Wang (2007)
Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies.
M. Reddy (2004)
10.2174/1568009023333836
Cancer-targeted polymeric drugs.
Y. Luo (2002)
10.1039/c2dt31812a
Multifunctional magnetic fluorescent hybrid nanoparticles as carriers for the hydrophobic anticancer drug 5-fluorouracil.
Swagatika Sahu (2013)
10.1211/146080899128734857
Antitumour Efficacy of Cyclodextrin-complexed and Niosome-encapsulated Plumbagin in Mice Bearing Melanoma B16F1
E. Oommen (1999)
Cyclodextrins—a review on pharmaceutical application for drug delivery
R. Agrawal andV.Gupta (2012)
10.1158/0008-5472.CAN-08-1776
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips (2008)
10.1016/S0169-409X(02)00044-3
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
Cyclodextrins
V J Stella (2008)
Physicochemical and biological studies of inclusion complex of methotrexate withcyclodextrin
U V Singh (1997)
10.1007/978-94-015-8277-3
Cyclodextrins in Pharmacy
Karl-Heinz Frömming (1993)
10.2174/138161206775201965
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy.
K. Takara (2006)
10.1016/j.biomaterials.2011.12.013
Multifunctional pH-disintegrable micellar nanoparticles of asymmetrically functionalized β-cyclodextrin-based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties.
T. Liu (2012)
10.1248/CPB.35.282
Complexation of several drugs with water-soluble cyclodextrin polymer.
J. Szemán (1987)
10.1007/S10847-010-9872-7
Effect of cyclodextrins on lonidamine release and in-vitro cytotoxicity
M. Lahiani-Skiba (2011)
10.1002/JPS.20721
Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.
Fangjing Wang (2006)
10.1002/1097-0142(19921215)70:12<2857::AID-CNCR2820701223>3.0.CO;2-2
Expression of the HER‐2/neu proto‐oncogene in serous ovarian neoplasms
J. Seidman (1992)
10.1021/JS980403L
Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs.
A. T. Serajuddin (1999)
10.1023/A:1023997501517
A monoclonal antibody to cyclomaltoheptaose (β-cyclodextrin): Characterization and use for immunoassay of β-cyclodextrin and its derivatives
K. Ikura (2004)
10.1016/S0169-409X(98)00092-1
Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development.
Szente (1999)
10.1002/JPS.20246
Solubilization and preformulation studies on PG-300995 (an anti-HIV drug).
Y. Ran (2005)
10.1021/JS980109T
Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether.
Y. Kim (1998)
A phase I study of trastuzumab-DM1, a first-in-class HER2 antibodydrug conjugate (ADC), given every 3 weeks to patients with HER2+metastatic breast cancer
M. Beeram (2008)
Cellular mechanisms of multidrug resistance of tumor cells.
A. Stavrovskaya (2000)
10.2165/00137696-200402040-00006
Role of cyclodextrins in improving oral drug delivery
T. Loftsson (2004)
10.1016/j.ejpb.2008.11.010
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
H. Maeda (2009)
10.1146/ANNUREV.BIOENG.9.060906.152025
Nanotechnology applications in cancer.
Shuming Nie (2007)
10.18433/J30C7D
Nanotherapeutics to overcome conventional cancer chemotherapy limitations.
M. Chidambaram (2011)
Solubilization of diazepam.
F. A. Alvarez Núñez (1998)
Szejtli, Cyclodextrins in Pharmacy, Kluwer Academic Publishers, Dortrecht
J.K.H. Froomming (1994)
Pure drug nanoparticles for the formulation of poorly soluble drugs
M. Radtke (2001)
Amonoclonal antibody to cyclomaltoheptaose (β-cyclodextrin): characterization and use for immunoassay of β-cyclodextrin and its derivatives
K. Ikura (2003)
10.2165/00063030-200620050-00004
A Supramolecular Complex between Proteinases and β-Cyclodextrin that Preserves Enzymatic Activity
Ângelo M. L. Denadai (2012)
10.1081/DDC-100102287
Solubilization of biphenyl dimethyl dicarboxylate by cosolvency.
S. Han (1999)
10.1016/j.colsurfb.2012.12.024
Hollow nanosphere fabricated from β-cyclodextrin-grafted α,β-poly(aspartic acid) as the carrier of camptothecin.
Junping Zeng (2013)
FORMULATION AND EVALUATION OF CURCUMIN LOADED MAGNETIC NANOPARTICLES FOR CANCER THERAPY
T. Silambarasi (2012)
10.1016/0378-5173(85)90220-0
Improvement of dissolution and absorption characteristics of phenytoin by a water-soluble β-cyclodextrin-epichlorohydrin polymer
K. Uekama (1985)
10.1007/S10847-008-9456-Y
Cyclodextrin based novel drug delivery systems
Amber Vyas (2008)
Cyclodextrins—a review on pharmaceutical application for drug delivery
R Agrawal (2012)
Cyclodextrinbased polymers for therapeutic delivery
A Glucksmann (2012)
ulating β - lapachone release from polymer millirods through cyclodextrin complexation
E. Blanco
10.1007/S10847-006-9085-2
Cyclodextrin-based Nanosponges for Drug Delivery
R. Cavalli (2006)
10.1002/jps.22496
Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Jingxia Cui (2011)
10.1021/mp100460h
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.
Cheoljin Kim (2011)
10.1039/C0JM03030A
Star-shaped polymers consisting of a β-cyclodextrin core and poly(amidoamine) dendron arms: binding and release studies with methotrexate and siRNA
Junjie Deng (2011)
A phase II study of trastuzumab-DM1(T-DM1), a HER2 antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
H. A. Burris (2008)
10.1002/CHIN.200929248
Cyclodextrin-based supramolecular polymers
Akira Harada (2006)
10.1016/j.ejpb.2009.04.013
Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.
Y. Çırpanlı (2009)
Cyclodextrins and Their Inclusion Complexes, Akadémiai Kiadó
J Szejtli (1982)
Synthesis and characterization studies of cisplatin/hydroxypropylí µí»½-cyclodextrin complex
A Balaji (2009)
10.1016/S0928-0987(02)00251-8
Nanosizing: a formulation approach for poorly-water-soluble compounds.
E. Merisko-Liversidge (2003)
10.1023/A:1021287920274
Comparison of the Complexation of Cosmetical and Pharmaceutical Compounds with γ-Cyclodextrin, 2-Hydroxypropyl-β-cyclodextrin and Water-Soluble β-Cyclodextrin-co-epichlorhydrin Polymers
A. Layre (2002)
10.1200/JCO.2008.26.15_SUPPL.1029
A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)
S. Holden (2008)



This paper is referenced by
10.1016/j.ultsonch.2018.05.017
Ultrasound-assisted biosynthesis of novel methotrexate-conjugates.
Jennifer Noro (2018)
10.1016/j.semcancer.2019.08.014
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges.
D. Kashyap (2019)
10.1007/978-3-319-76162-6_3
Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy
N. Erdoğar (2018)
10.1007/s00289-020-03323-z
Comparative studies of directly loaded and cyclodextrin-mediated release of Theophylline and evaluation of biodegradation studies of HPNs
K. Kaur (2020)
10.1016/j.jpba.2016.12.039
Cyclodextrins as inhibitors of the precipitation of riboflavin‐5’‐phosphate due to presence of zinc chloride: A NMR investigation
F. Aiello (2017)
10.1201/9781315370118-17
Basic Concepts in Drug Targeting: A Versatile Supramolecular System for Drug Delivery
Sabyasachi Maiti (2016)
10.1007/978-3-662-59119-2_2
Die Immunbarriere: Einfluss von Lebensmittelkomponenten auf die Darmbarriere
Christopher Beermann (2019)
10.1016/j.carbpol.2017.11.054
Synthesis of carbohydrate conjugated 6A,6D-bifunctionalized β cyclodextrin derivatives as potential liver cancer drug carriers.
Y. Ding (2018)
10.1016/j.heliyon.2019.e01405
Detailed chemical characterization and molecular modeling of serotonin inclusion complex with unmodified β-cyclodextrin
F. Fateminasab (2019)
10.2174/1385272823666190627115422
Cyclodextrins and their Derivatives as Carrier Molecules in Drug and Gene Delivery Systems
Ramin Karimian and Milad Aghajani (2019)
10.3390/ijms20030642
Cyclodextrin–Drug Inclusion Complexes: In Vivo and In Vitro Approaches
Simone Braga Carneiro (2019)
10.1088/1361-6528/ab529b
Lytic peptide-grafted beta-cyclodextrin polymer based nano-scaled drug delivery system with enhanced camptothecin anti-cancer efficacy.
Honglei Zhan (2019)
10.1007/978-3-030-49308-0_6
Cyclodextrin-Based Polymers for Food and Pharmaceutical Applications: A Historical Review
Max Petitjean (2020)
10.1208/s12249-016-0636-6
Enhancement of Bioavailability of Non-nucleoside Reverse Transciptase Inhibitor Using Nanosponges
Monica R. P. Rao (2016)
10.1080/10610278.2018.1562191
Facile synthesis of a diverse library of mono-3-substituted β-cyclodextrin analogues
Kathryn Kellett (2019)
10.3390/polym12040991
A Smart Strategy to Improve t-Resveratrol Production in Grapevine Cells Treated with Cyclodextrin Polymers Coated with Magnetic Nanoparticles
L. Almagro (2020)
10.1016/j.carbpol.2017.02.081
Preparation, characterization and in vitro biological evaluation of (1:2) phenoxodiol-β-cyclodextrin complex.
Eugene Yee (2017)
10.3390/ijms20205180
Cyclodextrin-Elicited Bryophyllum Suspension Cultured Cells: Enhancement of the Production of Bioactive Compounds
Pascual García-Pérez (2019)
10.1016/J.MOLLIQ.2019.111151
Inclusion complex of emodin with hydroxypropyl-β-cyclodextrin: Preparation, physicochemical and biological properties
N. Qiu (2019)
10.1038/s41598-019-41495-5
Liberibacter crescens biofilm formation in vitro: establishment of a model system for pathogenic ‘Candidatus Liberibacter spp.’
E. Naranjo (2019)
10.32553/IJMBS.V3I12.828
PREPARATION, CHARACTERIZATION AND EVALUATION OF CELECOXIB LOADED NANOSPONGES FOR THE TREATMENT OF PSORIATIC ARTHRITIS
G. S. Ravi (2019)
10.1007/s10973-020-09975-3
Instrumental analysis and molecular modelling of inclusion complexes containing artesunate
Denisa Cîrcioban (2020)
Cyclodextrin as a Drug Carrier Increasing Drug Solubility
M. Silberberg (2017)
10.1002/cbin.11139
JQ1, a BET‐bromodomain inhibitor, inhibits human cancer growth and suppresses PD‐L1 expression
Kaisheng Liu (2019)
10.1016/J.CARBPOL.2019.04.056
Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages.
Rubaiya Yunus Basha (2019)
10.1016/j.ijpharm.2020.119664
Cyclodextrin-grafted nanoparticles as food preservative carriers.
Leire Goni (2020)
10.3390/ph11010010
Self-Assembled Supramolecular Nanoparticles Improve the Cytotoxic Efficacy of CK2 Inhibitor THN7
Abdelhamid Nacereddine (2018)
10.1016/j.bpj.2019.03.016
Cholesterol Depletion by MβCD Enhances Cell Membrane Tension and Its Variations-Reducing Integrity
Arikta Biswas (2019)
Cell Biology International
Ying Xu (2019)
Chapter 1 Cyclodextrins : Past and Present
J. Martín (2018)
10.1016/j.xphs.2018.08.021
Remote Trice Light, Temperature, and pH-actuation of Switchable Magneto-Plasmonic Nanocarriers for Combinational Photothermal and Controlled/Targeted Chemotherapies.
Naby Hadilou (2018)
10.1007/978-981-13-0989-2_4
Isothermal Titration Calorimetry: A Powerful Tool for the Characterization of Molecular Interactions
Angelos Thanassoulas (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar